Register for our free email digests:
Neena Brizmohun
Her areas of expertise include the cutting-edge early market access schemes that are being trialed around the world for taking drugs and medical devices to market faster. She is also interested in initiatives for harmonizing regulations at the global level as well as issues affecting clinical trials, manufacturing and post-market safety monitoring. She explores the challenges and opportunities that these issues introduce for both industry and the regulators and is on a constant look out for what might be coming next.
A scientist by training, Neena started her journalistic career at Informa in 1997. She has been the deputy editor of Scrip Regulatory Affairs since 2007. Prior to that, she worked as the science editor for Clinica Medtech Intelligence. Before becoming a journalist she worked as a biomedical scientist at St Thomas' Hospital in London for 10 years.
Latest From Neena Brizmohun
First EMA Nod For Generic Xarelto; Apotex Pulls Upkanz For Neurodegenerative Disease
While Accord HealthCare has convinced the European Medicines Agency that its rivaroxaban generic should be approved in the EU, Bayer has warned that patent protection for Xarelto continues until at least late 2023. The EMA this week also recommend approval for a number of other new drugs.
Waylivra Funding Success In England & Germany
Akcea Therapeutics has lowered its asking price in England for its antisense therapy for familial chylomicronaemia syndrome. It has also struck a pricing and reimbursement deal for the drug in Germany.
Sanofi Seeks Double Vaccine Approval Nod In EU
The sponsors of up to seven new drugs or vaccines will find out this week whether their products will soon be approved in the EU. The products include two vaccines from Sanofi and what is possibly the first generic rival to Bayer's Xarelto to be assessed by the European Medicines Agency.
Routine UK Funding OKd For Tagrisso In First & Second-Line NSCLC
Health technology assessment body NICE has published two final guidance documents that cover the use of AstraZeneca’s drug at different points in the treatment pathway for locally advanced or metastatic EGFR-positive non-small cell lung cancer.
EU: BTG Tries Again With Voraxaze After 15 Years
Voraxaze, vosoritide and TransCon hGH are among the latest products that have been submitted to the European Medicines Agency for review for potential pan-EU marketing approval.
UK's NICE Backs Funding For Olympus Plasma System For BPH
The bipolar electrosurgery Plasma system reduces the risks associated with conventual monopolar transurethral resection of the prostate and works out cheaper, according to health technology assessment body NICE.